Carcinoid Tumors
February 2018 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Carcinoid Tumors abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Carcinoid Tumors. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Carcinoid Tumors. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Carcinoid Tumors every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content, Inc.

1:Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
Authors:Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Do Cao C, Lena H, Berruti A, Damiano V, Buikhuisen W, Gronbaek H, Lombard-Bohas C, Grohe C, Minotti V, Tiseo M, De Castro J, Reed N, Gislimberti G, Singh N, Stankovic M, Oberg K, Baudin E
Institution:Department of Medical Oncology, Multidisciplinary NET Group, Umbria Regional Cancer Network and University of Perugia, Perugia, Italy. Electronic address: London, London, UK. UK. Netherlands. Denmark. France.
Journal:Lancet Oncol. 2017 Dec;18(12):1652-1664. doi: 10.1016/S1470-2045(17)30681-2. Epub 2017 Oct 23.

2:Two-Stage Surgery Without Parenchyma Resection for Endobronchial Carcinoid Tumor.
Authors:Pikin O, Ryabov A, Sokolov V, Glushko V, Kolbanov K, Telegina L, Amiraliev A, Barmin V
Institution:Department of Thoracic Surgery, P. A. Hertzen Research Institute of Oncology, Moscow, Russia. Electronic address: Oncology, Moscow, Russia. Russia. Moscow, Russia. Moscow, Russia. Russia. Moscow, Russia. Moscow, Russia.
Journal:Ann Thorac Surg. 2017 Dec;104(6):1846-1851. doi: 10.1016/j.athoracsur.2017.06.050. Epub 2017 Oct 17.

3:Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
Authors:Masab M, Saif MW
Institution:Albert Einstein Medical Center, Philadelphia, PA, USA. Experimental Therapeutics, Tufts Medical Center, Tufts University School of Medicine, 800 Washington Street, Boston, MA, 02111, USA.
Journal:Cancer Chemother Pharmacol. 2017 Dec;80(6):1055-1062. doi: 10.1007/s00280-017-3462-y. Epub 2017 Oct 19.

4:Distinctive pathological and clinical features of lung carcinoids with high proliferation index.
Authors:Marchio C, Gatti G, Massa F, Bertero L, Filosso P, Pelosi G, Cassoni P, Volante M, Papotti M
Institution:Department of Medical Sciences, University of Turin, Via Giuseppe Verdi, 8, 10124, Turin, Italy. 7, 10126, Turin, Italy. Italy. 7, 10126, Turin, Italy. 10124, Turin, Italy. 7, 10126, Turin, Italy. 10124, Turin, Italy. Festa del Perdono, 7, I-20122, Milan, Italy. Group, Milan, Italy. 10124, Turin, Italy. 7, 10126, Turin, Italy. Italy. Italy. 7, 10126, Turin, Italy. Italy.
Journal:Virchows Arch. 2017 Dec;471(6):713-720. doi: 10.1007/s00428-017-2177-0. Epub 2017 Jun 19.

5:Carcinoid heart disease.
Authors:Hassan SA, Banchs J, Iliescu C, Dasari A, Lopez-Mattei J, Yusuf SW
Institution:Department of Cardiology, Division of Medicine, MD Anderson Cancer Center, Houston, Texas, USA.; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas, USA.
Journal:Heart. 2017 Oct;103(19):1488-1495. doi: 10.1136/heartjnl-2017-311261. Epub 2017 Jun 8.

6:Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience.
Authors:Herde RF, Kokeny KE, Reddy CB, Akerley WL, Hu N, Boltax JP, Hitchcock YJ
Institution:University of Utah School of Medicine. Institute, University of Utah, Salt Lake City, UT.
Journal:Am J Clin Oncol. 2018 Jan;41(1):24-29. doi: 10.1097/COC.0000000000000221.

For a FREE PREVIEW of the Medifocus Guidebook on Carcinoid Tumors click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Carcinoid Tumors click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Carcinoid Tumors...
at a Special 20% Discount

Medifocus Guidebook on Carcinoid Tumors

Updated: January 15, 2018
184 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Carcinoid Tumors is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: March 21, 2018

What Our Customers Are Saying...

"The MediFocus Guidebook on Carcinoid Tumors helped me prepare for my operation. It was reassuring to be able to communicate with my surgeon and the consulting doctors having knowledge about my condition."
Newcastle, England

"The Guide is detailed and written in a way that the layman can readily understand. My wife, who has just had a Carcinoid Tumor removed, is reading it as I write this. It will be helpful in her recovery and ongoing therapy."
Nanaimo, British Columbia

"The MediFocus Guidebook on Carcinoid Tumors was extremely informative and easy to understand. Now I'm able to discuss my condition with my doctor in an informed manner and make better decisions regarding my treatment."
Agoura Hills, California

Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.